Matinas BioPharma’s (MTNB) Hold Rating Reaffirmed at Maxim Group

Matinas BioPharma (NYSEAMERICAN:MTNB)‘s stock had its “hold” rating reiterated by investment analysts at Maxim Group in a research report issued on Thursday, Benzinga reports.

Matinas BioPharma Stock Down 68.1 %

MTNB traded down $1.32 during trading on Thursday, hitting $0.62. 2,865,360 shares of the stock were exchanged, compared to its average volume of 44,149. The company has a market capitalization of $3.09 million, a P/E ratio of -0.11 and a beta of 1.64. Matinas BioPharma has a 1 year low of $0.54 and a 1 year high of $21.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02).

Institutional Investors Weigh In On Matinas BioPharma

Large investors have recently bought and sold shares of the company. Towercrest Capital Management acquired a new position in shares of Matinas BioPharma during the 2nd quarter worth approximately $299,000. Alliance Wealth Management Group acquired a new position in shares of Matinas BioPharma during the 2nd quarter worth approximately $299,000. Finally, Highbridge Capital Management LLC acquired a new position in shares of Matinas BioPharma during the 2nd quarter worth approximately $1,685,000. 11.77% of the stock is currently owned by hedge funds and other institutional investors.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.